EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq: SRDX) , a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the signing of an expanded corporate technology agreement with St. Jude Medical, Inc. (NYSE: STJ). Under the agreement, SurModics has licensed multiple technologies for use in products being developed in St. Jude Medical’s Cardiovascular and Cardiac Rhythm Management divisions.
